Five-year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma

Hisashi Uhara1 | Yoshio Kiyohara2 | Jiro Uehara3 | Yasuhiro Fujisawa4 | Tatsuya Takenouchi5 | Masaki Otsuka2 | Hiroshi Uchi6 | Satoshi Fukushima7 | Hironobu Minami8 | Masahiro Hatsumichi9 | Naoya Yamazaki10

Abstract
We report the 5-year follow-up results from a single-arm, open-label, multicenter phase II study (ONO-4538-08) conducted in Japan. Twenty-four patients with treatment-naive, recurrent, or unresectable stage III/IV malignant melanoma received 3 mg/kg nivolumab every 2 weeks until progressive disease or unacceptable toxicity occurred. The 5-year overall survival (OS) rate was 26.1%. Five years after the start of nivolumab treatment, there were six survivors. The 5-year OS rate was 66.7% for patients with a superficial spreading type, 14.3% for acral lentiginous type, and 16.7% for mucosal type. The 5-year progression-free survival rate was 17.2%. No new cases of partial response or complete response were observed after 3 years, and overall response and disease control rates were similar to those reported at 3 years. The treatment-related adverse events reported between the 3- and 5-year follow-up periods were anemia (grade 2), white blood cell count decrease (grade 2), and psoriasiform dermatitis (grade 2) in one patient each. No new grade 3 or higher treatment-related adverse events occurred in this period. In conclusion, first-line treatment with nivolumab in Japanese patients with unresectable or metastatic melanoma resulted in confirmed long-term survival. No new safety signals were reported in the studied population.

KEYWORDS
Japan, long-term survivors, melanoma, nivolumab, survival

1Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan
2Dermatology Division, Shizuoka Cancer Center Hospital, Shizuoka, Japan
3Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
4Department of Dermatology, University of Tsukuba Hospital, Ibaraki, Japan
5Department of Dermatology, Niigata Cancer Center Hospital, Niigata, Japan
6Department of Dermato-Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
7Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
8Department of Medical Oncology/Hematology, Kobe University Graduate School of Medicine, Hyogo, Japan
9Ono Pharmaceutical Co., Ltd., Osaka, Japan
10Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan

Correspondence
Naoya Yamazaki, MD, PhD, Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Email: nyamazak@ncc.go.jp

Funding information
Ono Pharmaceutical; Bristol-Myers Squibb
1 | INTRODUCTION

Advanced malignant melanoma patients have an extremely poor prognosis. Among Japanese patients with advanced malignant melanoma (disease stage classified according to the Cancer Staging Manual, 7th Edition, of the American Joint Committee on Cancer), the 5-year disease-specific survival rate has been reported as 75.0% for stage IIIA, 61.3% for stage IIIB, 41.7% for stage IIIC, and 17.7% for stage IV. It should be noted that these survival estimates were calculated between 2005 and 2017, which means that these therapeutic efficacy assessments were made before the introduction of immune checkpoint inhibitors.

The anti-programmed death (PD)-1 monoclonal antibody nivolumab was first approved in 2014 as a treatment for previously untreated unresectable/recurrent malignant melanoma. Prior to that, dacarbazine was the standard treatment for melanoma, and nivolumab provided an important treatment option. After nivolumab was granted initial approval in 2014, further approval of nivolumab as first-line therapy was expected. To this end, a single-arm, open-label, multicenter phase II study in previously untreated Japanese patients with advanced (stage III or IV) or recurrent malignant melanoma (ONO-4538-08) was conducted and showed favorable efficacy and safety results with nivolumab treatment. Patients achieved an overall response rate (ORR) of 34.8% and an overall survival (OS) rate of 56.5% at 18 months. Based on these results, nivolumab was approved as a first-line treatment for advanced (stage III or IV) or recurrent malignant melanoma in Japan.

In CheckMate 066, an international phase III trial comparing nivolumab monotherapy with dacarbazine in patients with previously untreated BRAF wild-type malignant melanoma, the 3- and 5-year OS rates in the nivolumab monotherapy arm were 51.2% and 34%, respectively. In CheckMate 067, an international phase III trial that involved three treatment arms (nivolumab monotherapy, ipilimumab monotherapy, and nivolumab + ipilimumab) in patients with previously untreated malignant melanoma, the 3- and 5-year OS rates in the nivolumab monotherapy arm were 52% and 44%, respectively. However, predominant melanoma types are different between Japanese patients and non-Japanese patients. Acral lentiginous melanoma predominates in Japan (~40%), whereas the superficial spreading type predominates in other countries. The proportions of acral lentiginous and mucosal melanoma types in Japan are higher than those reported in other countries and, as these types are known to harbor tumor mutations far less frequently than the superficial spreading type, this may affect the effectiveness of nivolumab. Due to these differences, data confirming the long-term efficacy of nivolumab in Japanese melanoma patients are needed.

We previously reported the 3-year OS data in Japanese patients from the ONO-4538-08 study. Of 24 patients enrolled, there were 10 survivors, and the ORR and 3-year OS rate were 34.8% and 43.5%, respectively. Here, we report the 5-year follow-up results, including stratification by melanoma type. The baseline characteristics of Japanese melanoma patients who were long-term survivors are also reported.

2 | METHODS

2.1 | Study design

The study design of ONO-4538-08 has been described in a previous report. Briefly, the study was a single-arm, open-label, multicenter phase II study with three periods: screening, intervention, and post-treatment follow-up. Patients received nivolumab 3 mg/kg every 2 weeks as part of a 6-week cycle until progressive disease or unacceptable toxicity. At the end of every cycle, patients were evaluated by computed tomography or magnetic resonance imaging to determine if they would continue treatment.

Treatment discontinuation criteria have been described previously. Patients discontinued treatment if they presented complete response (CR), progressive disease (Response Evaluation Criteria in Solid Tumors [RECIST]), clinical signs of cancer progression, onset of grade 2 or more interstitial lung disease, grade 3 or more adverse events (AE), or grade 2 or more eye pain or reduced visual acuity grade that did not improve with topical treatment. If the treatment was discontinued, patients entered the follow-up stage.

2.2 | Patients

Patients enrolled in the study were Japanese individuals who had histopathologically confirmed unresectable stage III/IV or recurrent malignant melanoma based on the criteria from the Union for International Cancer Control TNM Classification of Malignant Tumors (7th edition). Additionally, enrolled patients had not previously received a systemic antineoplastic agent (e.g., chemotherapy, molecular targeted therapy, or immunotherapy), and had at least one measurable lesion by RECIST criteria (version 1.1). Previous pre- or postoperative adjuvant therapies for malignant melanoma were allowed if treatment had been concluded at least 6 weeks before enrollment, the condition of patients was stable, and all AE had reverted to the baseline conditions. Patients were excluded if they had a primary tumor in the esophagus or rectum or had multiple primary cancers.

2.3 | Ethics

The institutional review board of each participating site approved the study protocol. The study conduct conformed to the provisions of the Declaration of Helsinki (as revised in Fortaleza, Brazil, October 2013) and the International Conference on Harmonisation Guideline for Good Clinical Practice. All participants provided written informed consent prior to initiation of study treatment. This study was registered at www.clinicaltrials.jp under the number JapicCTI-142533.
2.4 | End-points

The primary end-point was centrally assessed ORR; other efficacy end-points were OS, progression-free survival (PFS), best overall response (BOR), disease control rate (DCR), and percent change in the sum of diameters of the target lesions. Additionally, ORR, OS, PFS, and DCR were analyzed by presence of BRAF V600 gene mutations in a subgroup analysis. Efficacy end-points were also stratified by melanoma type. The cut-off point for the sum of all diameters of the target lesions was determined using the quartile baseline tumor diameter (based on the first quartile [≤21.950 mm] and third quartile [>64.615 mm]). The safety end-points were AE, treatment-related AE, AE with potential immunological causes, and changes in vital signs, laboratory values, and 12-lead electrocardiograms.

2.5 | Statistical analysis

The sample size rationale and calculations, as well as the analysis populations, have been detailed previously. The planned overall sample size was at least 20 patients, of whom 14 were required to have BRAF wild-type melanoma and six to have BRAF mutant melanomas. Summary statistics were used to analyze the demographic and baseline characteristics of patients. For primary and secondary efficacy end-points, two-sided 90% confidence intervals (CI) were calculated. The Kaplan–Meier method was used for survival analysis. A subgroup analysis was performed to determine the efficacy of nivolumab according to the sum of tumor diameters at baseline and melanoma type. The statistical software used was SAS version 9.3 or higher (SAS Institute).

3 | RESULTS

3.1 | Patient characteristics

All 24 patients enrolled in the phase II (ONO-4538-08) study were evaluated in this analysis. The date of enrollment of the last patient was 9 October 2014. The data cut-off date was 31 October 2019. The baseline and demographic characteristics of patients have been described previously. Acral lentiginous type was the most common melanoma type (29.2% [n = 7]), followed by mucosal (25.0% [n = 6]), superficial spreading (25.0% [n = 6]), nodular (4.2% [n = 1]), and unknown (16.7% [n = 4]). Of the 24 patients included in the primary analysis, one nodular type patient was found to have multiple tumors after the study was initiated. This patient was excluded from the efficacy analysis in line with the prespecified exclusion criteria.

3.2 | Efficacy end-points

The median OS was 32.9 months, and the 4- and 5-year survival rates were 30.4% and 26.1%, respectively (Figure 1). The median PFS was 5.9 months, and the 4- and 5-year PFS rates were both 17.2% (Figure 2). The ORR was 34.8% (90% CI, 20.8–51.9). The DCR was 65.2% (90% CI, 48.1–79.2). There were no new cases of partial response (PR) or CR after 3 years, and the ORR and DCR were similar to those reported at 3 years.

Among patients with superficial spreading melanoma, the median OS was not reached, and the 5-year OS rate was 66.7%. The respective median OS and 5-year OS rates were 32.9 months and 14.3% for acral lentiginous type, 19.3 months and 16.7% for mucosal type, and 11.1 months and 0% for other types of melanoma (Figure 3a). The 5-year OS rate was higher for superficial spreading type than for mucosal and acral lentiginous types. The same tendency was observed for PFS (Figure 3b). The median OS for patients with BRAF mutation was not calculable because 50% of patients were still alive by the data cut-off; that for patients without BRAF mutation was 26.9 months (Figure S1a). The corresponding PFS data by BRAF mutation status are shown in Figure S1b.

Changes in tumor diameter for individual patients by melanoma subtype are shown in Figure 4, and long-term responses were observed in all three of the main melanoma subtypes. Figure 5 shows the individual treatment response and treatment progress by melanoma subtype. Five years after the start of nivolumab treatment, there were six survivors. Among these 5-year survivors, four had the superficial spreading type (66.7%), one had the acral lentiginous type (16.7%), and one had the mucosal type (16.7%). In the
17 patients who did not survive for 5 years (non-5-year survivors), two had the superficial spreading type (11.8%), six had the acral lentiginous type (35.3%), and five had the mucosal type (29.4%). In addition, among 5-year survivors, the BOR was CR in 50.0% (3/6), PR in 16.7% (1/6), and stable disease in 33.3% (2/6). Among the 5-year survivors, 83.3% (5/6 patients) had lactate dehydrogenase (LDH) levels below the upper limit of normal, 66.7% (4/6 patients) had vitiligo, and 33.3% (2/6 patients) had organ metastases. In non-5-year survivors, 64.7% (11/17 patients) had LDH levels below the upper limit of normal, 23.5% (4/17 patients) had vitiligo, and 41.2% (7/17 patients) had organ metastases.

Table S1 summarizes the results of the subgroup analysis of clinical efficacy measures, according to melanoma type. The ORR and DCR were 66.7% and 100%, 28.6% and 57.1%, 33.3% and 50.0%, and 0% and 50.0% for superficial spreading, acral lentiginous, mucosal, and other melanoma types, respectively. The median OS and PFS were not reached and 26.2 months, 32.9 and 8.5 months, 19.3 and 4.9 months, and 11.1 and 2.1 months for superficial spreading, acral lentiginous, mucosal, and other melanoma types, respectively. In this subgroup analysis, the patients with superficial spreading melanoma type tended to have higher OS, ORR, DCR, and PFS than patients with mucosal, acral lentiginous, and other melanoma types.

3.3 | Safety end-points

The treatment-related AE that occurred between the 3- and 5-year follow-up were anemia (grade 2), white blood cell count decreased (grade 2), and psoriasiform dermatitis (grade 1) in one patient each. No new grade 3 or higher treatment-related AE occurred during this period (data not shown). In addition, the safety profile during this period was similar to that described in the previous report, and no new safety signals were observed (Table S2).

4 | DISCUSSION

This analysis of the ONO-4538-08 study investigated the long-term efficacy (5-year OS and PFS) and safety of nivolumab for Japanese patients with untreated advanced or recurrent malignant melanoma. The 5-year OS rate was 26.1%, indicating that first-line treatment with nivolumab in Japanese patients with unresectable or metastatic melanoma resulted in long-term survival for some patients. However, the OS rate reported in the present study was lower than the rates reported in the CheckMate 066 trials (34% and 44%, respectively). It has been reported that the proportion of patients with acral lentiginous type and mucosal type melanoma is higher in Japan and other East Asian countries compared with the rest of the world.11–14 In this study, acral lentiginous type was the most common melanoma type (29.2%), followed by mucosal type (25.0%). In contrast, a study in Caucasians reported that the proportion of acral lentiginous and mucosal types was 3.0% and 6.9%, respectively.15 In our analysis, the 5-year OS rate was 66.7% in patients with superficial spreading melanoma, and this rate was higher than that in patients with acral lentiginous (14.3%) and mucosal (16.7%) types. The same tendency was observed for PFS. These results were also similar to those reported in the 3-year analysis.4 Poor prognosis in Japanese patients with mucosal and acral lentiginous types has also been reported in another study in which patients were administrated anti-PD-1 antibodies.16 Overall, these findings suggest that the melanoma type may affect prognosis in patients treated with anti-PD-1 antibodies. One potential reason for these differences may be related to the tumor mutational burden (TMB). Reportedly, the TMB is low in the acral lentiginous and mucosal types compared with the superficial spreading type.17 In cancer cells with a high TMB, the immune system is thought to more easily recognize the tumor due to increased neoantigen levels. This might explain the variable response to nivolumab between the superficial spreading type and acral lentiginous and mucosal types.

The incidence of grade 3 or more treatment-related AE in our analysis was 12.5%, and no new safety signals were identified when compared with the initial (18-month) and 3-year analyses.4,5 The ONO-4538-17 study18 reported that 76.7%...
of patients in the nivolumab + ipilimumab group had grade 3–4 treatment-related AE compared with 12.5% of patients in the nivolumab group in this study. Numerically, patients receiving nivolumab + ipilimumab combination therapy had a high incidence of grade 3–4 treatment-related AE, a tendency that was also reported in the nivolumab + ipilimumab combination therapy arm.
of the CheckMate 067 trial.\textsuperscript{9,10} Thus, the incidence of grade 3 or more treatment-related AE should be considered when choosing treatment based on melanoma type. However, because of the small sample size and limited number of reports, further studies are needed to clarify the relationship between immune checkpoint inhibitor efficacy and disease type.

There were six survivors at 5 years after the start of nivolumab treatment in the present study. Among these six, the BOR was variable (CR in 50.0% [3/6], PR in 16.7% [1/6], and stable disease in 33.3% [2/6]). However, the survivors seemed to have some characteristics in common, including a superficial spreading disease type (67%, 4/6 patients), a serum LDH level below the upper limit of normal (83%, 5/6 patients), and vitiligo (67%, 4/6 patients). The values of these factors were numerically higher among 5-year survivors compared with non-5-year survivors, and these relationships were similar to those observed in previous reports.\textsuperscript{6,19–24} Of note, the relationship between the onset of vitiligo and the efficacy of nivolumab is somewhat unclear. Two patients among the 5-year survivors did not develop vitiligo during nivolumab treatment and two of the four 5-year survivors who developed vitiligo experienced these events after the initial response. Therefore, further assessment of this relationship is needed.

### Figure 5

Swimmer plot showing individual treatment progress by melanoma type. \textsuperscript{a}Although nivolumab treatment was discontinued at the end of the study, two patients continued to receive post-treatment nivolumab. PD-L1+ indicates positive (≥1%) and PD-L1− indicates negative (<1%). L indicates LDH upper limit of normal and H indicates LDH >upper limit of normal. BOR, best overall response; CR, complete response; H, high; IND, indeterminable; L, low; LDH, lactate dehydrogenase; Mut, BRAF mutant; NE, not evaluable; PD, progressive disease; PD-L1, programmed death ligand 1; PR, partial response; SD, stable disease; WT, BRAF wild-type.

| BOR | BRAF | PD-L1 | LDH | Number of metastatic organs |
|-----|------|-------|-----|----------------------------|
| CR  | Mut+ | L     | 2   |                            |
| PR  | Mut− | L     | 0   |                            |
| SD  | Mut− | L     | 0   |                            |
| SD  | WT   | IND   | L   | 0                          |
| CR  | WT   | +     | L   | 1                          |
| PR  | Mut− | L     | ≥3  |                            |
| CR  | WT   | NE    | L   | 1                          |
| SD  | WT   | −     | L   | 0                          |
| PR  | Mut− | H     | ≥3  |                            |
| SD  | WT   | +     | L   | 0                          |
| PD  | Mut− | H     | ≥3  |                            |
| PD  | WT   | NE    | L   | 0                          |
| PD  | WT   | −     | L   | 0                          |

| BOR | BRAF | PD-L1 | LDH | Number of metastatic organs |
|-----|------|-------|-----|----------------------------|
| CR  | WT   | NE    | H   | 0                          |
| PR  | WT   | −     | L   | 1                          |
| SD  | WT   | −     | H   | 0                          |
| PD  | WT   | −     | L   | 0                          |
| PD  | WT   | −     | H   | 0                          |
| SD  | WT   | −     | L   | 0                          |
| SD  | WT   | NE    | L   | 2                          |
| PD  | WT   | −     | H   | 0                          |

- End of treatment due to physician decision (Due to end of study)
- End of treatment due to response
- End of treatment due to physician decision (Other)
- Discontinuation of trial due to progressive disease

| Months |
|--------|
| 0 | 6 | 12 | 18 | 24 | 30 | 36 | 42 | 48 | 54 | 60 | 66 |

- Administration period
- Period after administration
- Period after post treatment
- First response
- Vitiligo
- Censored

End of treatment due to physician decision (Due to end of study)
End of treatment due to response
End of treatment due to physician decision (Other)
Discontinuation of trial due to progressive disease

- Discontinuation of trial due to progressive disease

*Figure 5* Swimmer plot showing individual treatment progress by melanoma type. \textsuperscript{a}Although nivolumab treatment was discontinued at the end of the study, two patients continued to receive post-treatment nivolumab. PD-L1+ indicates positive (≥1%) and PD-L1− indicates negative (<1%). L indicates LDH supr face limit of normal and H indicates LDH >upper limit of normal. BOR, best overall response; CR, complete response; H, high; IND, indeterminable; L, low; LDH, lactate dehydrogenase; Mut, BRAF mutant; NE, not evaluable; PD, progressive disease; PD-L1, programmed death ligand 1; PR, partial response; SD, stable disease; WT, BRAF wild-type.
The main limitations of this study have been previously described, and consist mainly of the open-label design, the lack of a comparator, and the small sample size. The results presented here should be confirmed in a large-scale clinical trial.

In conclusion, first-line treatment with nivolumab in Japanese patients with unresectable or metastatic melanoma resulted in long-term survival for some patients. No new safety signals were reported in the studied population.

ACKNOWLEDGMENTS
The authors are grateful to the patients and their families, and to the investigators, nurses, and staff members who participated in this study. We would like to thank the late Dr Hironobu Inn of Kumamoto University for his support in the conduct of the study. This study was funded by Ono Pharmaceutical and Bristol-Myers Squibb. All authors had full access to all of the data in the study and had final responsibility for the decision to submit for publication. The authors wish to thank Keyra Martinez Dunn, MD, of Edanz Evidence Generation for providing medical writing support, which was funded by Ono Pharmaceutical and Bristol-Myers Squibb through EMC KK in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

CONFLICT OF INTEREST
H. Uhara has received honoraria from Ono Pharmaceutical and Novartis, manuscript fees from Ono Pharmaceutical, and research funding from Ono Pharmaceutical, Maruho, Taiho Pharmaceutical, and Torii. Y.F. has received honoraria from Novartis and research funding from Eisai. T.T. has received honoraria from Ono Pharmaceutical, MSD, Novartis, and Bristol-Myers Squibb. S.F. has received grants from Ono Pharmaceutical. H.M. has received honoraria from Ono Pharmaceutical and grants from Ono Pharmaceutical and Bristol-Myers Squibb. M.H. is an employee of Ono Pharmaceutical. N.Y. has received honoraria from Ono Pharmaceutical, Novartis, Bristol-Myers Squibb, MSD, Chugai, Takeda, and Merck, and research funding from Ono Pharmaceutical, Novartis, MSD, Bristol-Myers Squibb, Merck, Takara Bio, and Sysmex. Y.K., J.U., M.O., and H. Uchi have no conflict of interest related to this research.

ORCID
Yasuhiro Fujisawa https://orcid.org/0000-0003-3010-8496
Satoshi Fukushima https://orcid.org/0000-0002-0622-7682
Naoya Yamazaki https://orcid.org/0000-0002-9638-0428

REFERENCES
1. American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. Chicago, IL: Springer; 2015.
2. Fujisawa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H, et al. Classification of 3097 patients from the Japanese melanoma study database using the American Joint Committee on Cancer eighth edition cancer staging system. J Dermatol Sci. 2019;94(2):284–9. https://doi.org/10.1016/j.jdermsci.2019.04.003
3. Fujisawa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H, et al. Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. Cancer Med. 2019;8(5):2146–56. https://doi.org/10.1002/cam4.2110
4. Yamazaki N, Kiyohara Y, Uhara H, Uehara J, Fujisawa Y, Takenouchi T, et al. Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma. Cancer Sci. 2019;110(6):1995–2003. https://doi.org/10.1111/cas.14015
5. Yamazaki N, Kiyohara Y, Uhara H, Uehara J, Fujimoto M, Takenouchi T, et al. Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: a phase II study. Cancer Sci. 2017;108(6):1223–30. https://doi.org/10.1111/cas.13241
6. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30. https://doi.org/10.1056/NEJMoa1412082
7. Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA Oncol. 2019;5(2):187–94. https://doi.org/10.1001/jamaoncol.2018.4514
8. Robert C, Grob JJ, Stroyakovsky D, Karasewszka B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626–36. https://doi.org/10.1056/NEJMoa1904059
9. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowskii P, Grob J-J, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–56. https://doi.org/10.1056/NEJMoa1709684
10. Larkin J, Chiarion-Sileni V, Gonzalez R, Rutkowskii P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–46. https://doi.org/10.1056/NEJMoa1910836
11. Japanese melanoma study: annual report 2017. [Cited 2020 June 3]. http://www.skincancer.jp/report-skin-cancer_melanoma_2017.pdf. Accessed 30 Sept 2020.
12. Tsoutsos D, Papadopoulos S, Kehagias G, Mara A, Kyriopoulos E, Karonis A, et al. Epidemiological trends in the diagnosis of melanoma in a Southern European population: analysis of a large database from a tertiary referral center. Melanoma Res. 2018;28(4):348–58. https://doi.org/10.1097/cmr.0000000000000456
13. Higgins S, Nazemi A, Feinstein S, Chow M, Wysong A. Clinical presentations of melanoma in African Americans, Hispanics, and Asians. Dermatol Surg. 2019;45(6):791–801. https://doi.org/10.1097/dss.0000000000001759
14. Chang JW. Acral melanoma: a unique disease in Asia. JAMA Dermatol. 2013;149(11):1272–3. https://doi.org/10.1001/jamadermatol.2013.5941
15. Kuk D, Shousharti AN, Barker CA, Panageas KS, Munzor RR, Moutaz P, et al. Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis. Oncologist. 2016;21(7):848–54. https://doi.org/10.1634/theoncologist.2015-0522
16. Nakamura Y, Fujisawa Y, Tanaka R, Maruyama H, Ishitsuka Y, Okiyama N, et al. Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: retrospective single institutional study. J Dermatol. 2018;45(11):1337–9. https://doi.org/10.1111/j.1346-8138.2018.14637
17. Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545(7653):175–80. https://doi.org/10.1038/nature22071
18. Namikawa K, Kiyohara Y, Takenouchi T, Uhara H, Uchi H, Yoshikawa S, et al. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: an open-label, single-arm, multicentre phase II study. Eur J Cancer. 2018;105:114–26. https://doi.org/10.1016/j.ejca.2018.09.025
19. Ascierto PA, Vanella V, Grimaldi AM, Lucia F, Palla M, Simeone E, et al. Complete response to nivolumab monotherapy in a treatment-naïve, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial. *Cancer Immunol Immunother*. 2016;65(11):1395–400. https://doi.org/10.1007/s00262-016-1898-2

20. Diem S, Kasenda B, Spain L, Martin-Liberal J, Marconcini R, Gore M, et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. *Br J Cancer*. 2016;114(3):256–61. https://doi.org/10.1038/bjc.2015.467

21. Bystryn JC, Rigel D, Friedman RJ, Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. *Arch Dermatol*. 1987;123(8):1053–5.

22. Nakamura Y, Tanaka R, Asami Y, Teramoto Y, Imamura T, Sato S, et al. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study. *J Dermatol*. 2017;44(2):117–22. https://doi.org/10.1111/1346-8138.13520

23. Quaglino P, Marenco F, Osella-Abate S, Cappello N, Ortoncelli M, Salomone B, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. *Ann Oncol*. 2010;21(2):409–14. https://doi.org/10.1093/annonc/mdp325

24. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: a good prognostic sign. *J Am Acad Dermatol*. 1983;9(5):689–96. https://doi.org/10.1016/s0190-9622(83)70182-9

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.